Company Receives International Orders for Over 3 Million Units in the Next 13 Months, Immediately Raises Monthly Factory Output to 620,000 Units
LOS ANGELES, CA / ACCESSWIRE / November 30, 2016 / Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service, and regulatory processes agent for GenStrip™ 50 and the GenUltimate!™ glucose test strips, both designed to work with the market leading Johnson & Johnson's ("J&J") LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure!™ and GenChoice!™ glucose test strips targeted to the U.S. and/or developing world markets today conveys recent marketing plan advancements and new international distributor additions.
Since the landmark conclusion of the successful litigation defense to the imaginary patent infringement allegations filed by J&J, the company has focused its energies and resources towards the precise execution of its formal marketing plan. Several recent communications to its shareholders and the broader investment community were highlighted by the pursuit and completion of the initial phase of that Plan. Hundreds of on-line retail merchandising venues had been added and through which Gen family of test strip revenue had begun flowing. That successful tactical campaign continues to increase distribution point locations and expand individual location footprint. In anticipation of this accelerated demand, factory capacity has been increased by the Pennsylvania and the South Korea contract manufacturers to 620,000 GenUltimate! units per month.
Concurrent to that on-line escalation, the company initiated the second chapter of its detailed Plan with the targeting and contracting of a global network of international distributors. That network remains in development and its conclusion is not shortly expected, however, initial progress has yielded short term positive accomplishments; two of which the company would like to share with its loyal shareholders:
- Uni-Care Corp
Seoul, South Korea
- Macre Diagnosis S.R.L.
Santa Cruz, Bolivia
Both of these newly added international distributors will represent the company's GenUltimate!, GenSure! and GenChoice! product line in multiple nations. The agreement requires that each distributor maintain a local sub-distributor in each individual nation within their territorial exclusive.
Keith Berman, PEO of Decision Diagnostics commented, "It is gratifying and highly appropriate that immediately following the Thanksgiving holiday we are in a position to update our shareholders and the entire investment community regarding the continuation of our efforts to execute our marketing plan, and to communicate the initial fruits of those tactical endeavors. We are all thankful for the loyalty of our investors and the support of our customers."
The Company has contracted Uni-Care Corp to exclusively distribute the Gen family of test strips to the Republic of South Korea, China and the Philippines. Uni-Care has activated the arrangement with the submission of an initial stocking purchase order for approximately 40,000 pieces of GenUltimate! test strips to be shipped immediately following the product's registration with South Korea's KFDA regulatory agency, expected in early December. Additional stocking orders are expected from sub-distributors in China and the Philippines. The Uni-Care Exclusive Distribution Agreement requires the annual purchase of a minimum of 250,000 GenUltimate! units in the next 12 months.
Macre Diagnostics S.R.L. has become the company's distributor to multiple countries in South America. Macre, located in Santa Cruz, Bolivia has secured its regulatory approvals and has placed an initial opening order for 10,800 pieces of GenUltimate! with a 12 month cumulative order for 2,850,000 pieces of GenUltimate!
Mr. Berman continued, "Five years ago we committed to defeating J&J in the courts, regardless of the cost, in order to recapture our right to manufacture and sell our superior line of blood glucose test strips anywhere and to anyone without fear of interference or reprisal. That battle has ended and we were overwhelmingly victorious. We are now well into our new campaign targeting the global markets that supply the diabetic test strip to their ever-growing diabetic populations. The two newly contracted international distributor accounts that we have recently added to our network, and about which we are now communicating, is an impressive beginning. Our investors can expect to hear more similar conquests as we proceed into 2017."
This release contains the Company's forward-looking statements which are based on management's current expectations and assumptions as of November 29, 2016, regarding the Company's business and performance, its prospects, current factors, the economy and other future conditions and forecasts of future events, circumstances and results.
Decision Diagnostics Corp.
SOURCE: Decision Diagnostics Corp.